Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CAMBRIDGE NUTRITIONAL SCIENCES PLC Director's Dealing 2022

Jun 8, 2022

7544_pos_2022-06-08_61421af6-ded3-4ff9-bb6d-3c9ed1780188.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 1870O

Omega Diagnostics Group PLC

08 June 2022

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

PDMR/Director Dealing

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that, following the general meeting held on 6 June 2022 and Admission on 8 June 2022, the following Directors participated in the Fundraising and their resultant holdings are detailed in the table below.

Director Board Position Number of Subscription Shares at the Issue Price Amount (£) Resultant holding Resultant percentage holding of Enlarged Issued Share Capital
Simon Douglas1 Chairman 500,000 20,000 500,000 0.21%
Jag Grewal2 CEO 500,000 20,000 735,746 0.31%
Chris Lea3 CFO 500,000 20,000 500,000 0.21%
Jeremy Millard4 Non-Executive Director 500,000 20,000 1,025,000 0.43%

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 13 May 2022.

Contacts: 

Omega Diagnostics Group PLC www.omegadx.com
Jag Grewal, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)
Alice Lane/ Harriet Ward (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

Details of the person discharging managerial responsibilities / person closely associated 

a)

Name

1)    Simon Douglas

2)    Jag Grewal

3)    Chris Lea

4)    Jeremy Millard

2

Reason for the notification

a)

Position/status

1)    Chairman

2)    Chief Executive Officer

3)    Chief Financial Officer

4)    Non-Executive Director

b)

Initial notification /Amendment 

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) 

Name 

Omega Diagnostics Group Plc

b) 

LEI 

2138007U9P4BTZTYIR92

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 4 pence each 

ISIN: GB00B1VCP282

b) 

Nature of the transaction 

Purchase of Shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
1) £0.04 500,000
2) £0.04 500,000
3) £0.04 500,000
4) £0.04 500,000

d)

Aggregated information 

-Aggregated volume 

- Price 

N/A - single transaction for each Director or PCA

e) 

Date of the transaction

6 May 2022

f) 

Place of the transaction

London Stock Exchange (AIM)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBKFBQBBKDAAK